StoneX Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

StoneX Group’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,234	Closed	-$18.7K	–	1111
2025 Q4	$18.7K	Buy	+16,234	New	+$22.3K	﹤0.01%	975

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

StoneX Group's LXRX Position: Q1 2026 in Review

StoneX Group sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2026, closing a stake of 16,234 shares — an estimated $18.7K sold.

StoneX Group first reported a position in LXRX in Q4 2025 and held it in 1 quarter. The position peaked at $18.7K in Q4 2025. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

StoneX Group reported no remaining Lexicon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 16,234 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $18.7K.
StoneX Group first reported a position in Lexicon Pharmaceuticals in Q4 2025 and held it in 1 quarter.
StoneX Group's Lexicon Pharmaceuticals position peaked at $18.7K in Q4 2025.
136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.